AXLRx Book a callCommission

Rare Disease · United Kingdom · In-Market

UK Pompe Disease KOL Mapping

A six-physician BIMDG subcommittee advises NICE directly on Pompe disease. It sits at the centre of a five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.

Assess this report See what's inside ↓ Reviewed by Naresh Gupta, Founder & Director Last updated August 2026
Market GCC (Gulf) United Kingdom Stage

Key takeaways

  • 5 academic-clinical centres in the UK Pompe Consortium network: GSTT/King's, Manchester, Birmingham, Addenbrooke's, and Edinburgh
  • 8 NHS Pompe Highly Specialised Service centres delivering enzyme replacement therapy nationally
  • 80-100 patients in Royal Free London's cohort, the single largest concentration in the NHS Pompe HSS network
  • 6 KOL Mapping gates (K1-K6), each independently verified before a name enters the workbook

The UK Pompe Consortium's five academic centres and the NHS's eight Highly Specialised Service sites concentrate expertise around a six-physician BIMDG subcommittee that advises NICE directly.

UK Pompe disease expertise concentrates around a defined academic-clinical network, not a broad national field. The UK Pompe Consortium coordinates shared care, a national registry, and research across five centres: GSTT/King's, Manchester, Birmingham, Addenbrooke's, and Edinburgh. Enzyme replacement therapy is delivered through the NHS Pompe Highly Specialised Service, eight centres nationally, anchored by Royal Free London's cohort of roughly 80 to 100 patients, the network's single largest concentration. A coordinated, registry-backed academic network of this kind does not form without an established referral and collaboration structure. Our KOL Universe gate (K1) starts by mapping exactly this kind of institutional concentration before any single physician is scored.

That structure changes how AXLRx tiers influence in the UK. A metabolic physician sitting on the British Inherited Metabolic Disease Group's Pompe subcommittee, six physicians drawn from across the eight NHS Highly Specialised Service centres who advise NICE directly, carries a different weight than one working outside that advisory structure, and our Tier Classification gate (K2) scores that distinction directly, alongside FVC/6MWT monitoring capability and NICE-facing institutional roles. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over NICE-facing peers, which is exactly what the K1-K6 gate structure is built to prevent.

The UK Pompe Consortium and NHS Highly Specialised Service network — five academic centres, eight treatment sites

CONSORTIUM STRUCTURE
InstitutionRoleNetwork
Guy's and St Thomas' / King's College HospitalAdult metabolic disease, shared careUK Pompe Consortium
Manchester (Manchester Centre for Genomic Medicine)GAA enzyme assay site, shared careUK Pompe Consortium
BirminghamGAA enzyme assay site, shared careUK Pompe Consortium
Addenbrooke's, CambridgeShared care, metabolic geneticsUK Pompe Consortium
Edinburgh (Queen Elizabeth)Shared care, metabolic geneticsUK Pompe Consortium
Royal Free LondonLargest single patient cohort (~80-100 patients)NHS Pompe Highly Specialised Service

Sources: UK Pompe Consortium registry 2023; UK Pompe Consortium diagnostic pathway guidelines 2022; NHS England Pompe Highly Specialised Service specification; BIMDG Pompe subcommittee guidance.

What this workbook answers

Every section answers a named commercial question your team is asking, scoped to your asset.

  1. Which UK institutions actually generate the published evidence and NICE-facing advisory input that shapes Pompe disease treatment, and how concentrated is that network? • The UK Pompe Consortium's five-centre academic network • The eight-centre NHS Highly Specialised Service structure • K1 KOL Universe Sizing methodology
  2. How does AXLRx tier scientific and advisory influence across a national NICE-facing subcommittee without relying on publication count alone? • K2 Tier Classification methodology • BIMDG Pompe subcommittee membership and NICE-advisory weighting • K3 Scientific Influence scoring inputs
  3. What verification standard does every named KOL have to clear before shipping in the workbook? • The three-tag verification protocol (Verified/Industry benchmark/Requires client validation) • Live publication and institutional-affiliation cross-checks • Why no placeholder name ships unflagged
What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

  1. 1 · The Binding Constraint 2 pp
    • Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
    • Pressure-tested against the UK Pompe Consortium and NHS Highly Specialised Service case before the rest of the workbook is built out
  2. 2 · KOL Universe (K1) 4 pp
    • Every UK Pompe disease KOL sized and sourced from publication and institutional-affiliation data
    • The UK Pompe Consortium's five-centre network and the NHS's eight Highly Specialised Service sites as the sizing anchor
    • Universe boundaries: who counts as a KOL versus a high-volume prescriber
  3. 3 · Tier Classification (K2) 3 pp
    • Scientific and advisory-influence scoring across BIMDG Pompe subcommittee membership and NICE-facing institutional roles
    • What separates a Tier 1 KOL from a high-volume community prescriber
  4. 4 · Scientific Influence (K3) 3 pp
    • Influence inputs: NICE-facing advisory role, FVC/6MWT monitoring capability, institutional role
    • Cross-checked against independent publication and citation data
  5. 5 · Engagement Readiness (K4) 3 pp
    • Readiness scoring and channel recommendations per KOL
    • Sequencing implications for MSL deployment
  6. 6 · MSL Territory Coverage (K5) 3 pp
    • Territory-to-KOL coverage map across the UK Pompe Consortium and NHS HSS centres
    • Where current MSL deployment has gaps
  7. 7 · Cross-Border Network (K6) 3 pp
    • Multi-market reach for KOLs active beyond the UK, across EU5 metabolic disease networks
    • Implications for coordinated versus purely local engagement
  8. 8 · Client Alignment Questions 2 pp
    • The open KOL-engagement questions your medical affairs team must close
    • Structured for an internal alignment session before MSL deployment

Appendix and source ledger included · 45-minute analyst readout included with delivery

Custom workbook delivered in 72 hours.

Assess this report

Included with every brief

PDF
PDF Brief
KOL Mapping Brief — Summary Edition
PDF summary brief: tier strip, KOL universe table, and geographic breakdown for UK Pompe disease.
XLS
Excel Model
KOL Mapping Workbook — Excel
6-sheet editable workbook: KOL Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register.

Get Started

Commission this workbook

AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging UK Pompe disease specialists. Custom workbook in 72 hours.

  1. 1. Submit your requestSpecify your indication, geography, and institution scope.
  2. 2. Scoping callAXLRx analyst confirms institution scope and verification standard before building.
  3. 3. DeliveryResearch-verified KOL workbook in 72 hours with optional analyst readout.
Assess this report View sample workbooks

How AXLRx builds this workbook

Prepared by MoatRx analysts on the AXLRx commercial consulting engine.

Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.

UK Pompe disease KOL sources: UK Pompe Consortium registry 2023, UK Pompe Consortium diagnostic pathway guidelines 2022, NHS England Pompe Highly Specialised Service specification, and BIMDG Pompe subcommittee guidance.

  • UK Pompe Consortium centre list verified against UK Pompe Consortium registry 2023
  • NHS Pompe Highly Specialised Service centre count and Royal Free London cohort size verified against NHS England Pompe Highly Specialised Service specification
  • BIMDG Pompe subcommittee membership count verified against BIMDG Pompe subcommittee guidance
  • Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation

Frequently asked questions

Deliverables What formats are included with every workbook?

Every commissioned KOL Mapping workbook includes an editable 6-sheet Excel workbook (KOL Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register) and a PDF summary brief. No PowerPoint deck — this deliverable is built to be worked in directly. An optional 45-minute analyst readout call is included.

Sources How are KOL identities and rankings verified?

Every KOL entry is built from UK Pompe Consortium registry and diagnostic-pathway documentation, the NHS England Pompe Highly Specialised Service specification, and metabolic medicine guideline records, then tagged Verified, Industry benchmark, or Requires client validation. No name ships unverified.

Customisation Can I scope this to a specific centre set or NHS region?

Yes. The intake form captures your indication, geography, and centre scope. A scoping call confirms scope before research starts. Commission via the intake form to start.